How does lipitor influence intracellular protein processing?

How does Lipitor affect protein breakdown inside cells?

Lipitor contains atorvastatin, which lowers cholesterol mainly by blocking HMG-CoA reductase. This enzyme sits in the liver and produces cholesterol inside cells. Blocking it cuts the supply of cholesterol and isoprenoids made along the same pathway. These isoprenoids normally attach to proteins during prenylation, a step that helps proteins anchor to cell membranes and move correctly through the cell.

When isoprenoid supply drops, many proteins stay un-prenylated. They then pile up in the cytoplasm instead of reaching their normal destinations. This changes how proteins interact with membranes and interferes with signaling pathways such as Ras, Rho, and Rac, which are linked to cell growth and inflammation. The altered signaling indirectly affects how cells recycle or degrade proteins through the ubiquitin-proteasome system and autophagy.

What happens if the supply of isoprenoids is restored?

Adding back geranylgeranyl pyrophosphate or farnesyl pyrophosphate can reverse many of these effects. These isoprenoids bypass the blocked HMG-CoA reductase step and lie downstream of Lipitor’s action. Supplying them directly to cells shows that the changes in intracellular protein handling are driven chiefly by the isoprenoid shortage rather than by the allgemeine cholesterol drop alone.

Why are companies challenging this patent?

Lipitor’s patent on the active ingredient was challenged mainly by generic makers looking to launch early. The challenges focused on obviousness and patentability of the open-ring acid form of atorvastatin calcium. Companies such as Ranbaxy and Pfizer settled disputes before full court rulings. [1]

When does exclusivity expire?

Exclusivity for the original Lipitor formulation ended in 2011. Since then, generics entered the market and drove price down sharply. [2]

DrugPatentWatch.com